Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial. Eur Urol. 2025;88:373-380.
사설/논평
0/5 보강
APA
Palmstedt E, Hugosson J, Arnsrud Godtman R (2025). Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial. Eur Urol. 2025;88:373-380.. European urology, 88(6), e122. https://doi.org/10.1016/j.eururo.2025.09.4130
MLA
Palmstedt E, et al.. "Reply to Kevin B. Ginsburg, Ava Zamani, and Tudor Borza's Letter to the Editor re: Emmeli Palmstedt, Marianne Månsson, Jonas Hugosson, Rebecka Arnsrud Godtman. Active Surveillance for Screen-detected Low- and Intermediate-risk Prostate Cancer: Extended Follow-up up to 25 Years in the GÖTEBORG-1 Trial. Eur Urol. 2025;88:373-380.." European urology, vol. 88, no. 6, 2025, pp. e122.
PMID
40998630 ↗